Trials / Terminated
TerminatedNCT04324840
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-90010 | Specified dose on specified days |
| DRUG | Temozolomide | Specified dose on specified days |
| RADIATION | Radiotherapy | Specified dose on specified days |
Timeline
- Start date
- 2020-07-10
- Primary completion
- 2024-07-09
- Completion
- 2024-07-09
- First posted
- 2020-03-27
- Last updated
- 2024-07-26
Locations
29 sites across 7 countries: United States, Denmark, Italy, Netherlands, Norway, Spain, Sweden
Source: ClinicalTrials.gov record NCT04324840. Inclusion in this directory is not an endorsement.